Incoming administration could appoint key legal and policy positions to shape agenda’s agenda.
As President-elect Trump's transition continues, FDA soon will find out whether his influence will stretch deep inside the agency. High level policy and legal positions that have been filled with career FDA staff could become administration appointees in part to ensure the agency is in line with Trump's and HHS Secretary nominee Tom Price's agendas.
Marc Scheineson, head of the food and drug law practice at Alston and Bird and former FDA associate commissioner for...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
